7 completed, 5 unknown, 1 recruiting, 1 terminated. 5 Phase 4, 4 Phase 3, 3 Not applicable, 1 Early Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 5 | Completed 2, Unknown 2, Terminated 1 |
| Phase 3 | 4 | Completed 2, Recruiting 1, Unknown 1 |
| Not applicable | 3 | Completed 2, Unknown 1 |
| Early Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Unknown 1 |
Follow Cetrorelix acetate: new trials by email Literature Review of Cetrorelix acetate trials Research Report on Cetrorelix acetate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA) Follitropin alfa/lutropin alfa (MBJ-0011), hMG, Cetrorelix acetate - Infertility | Phase 3 | Recruiting | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 266 | 2026-02-04 | 2026-09-08 |
| Efficacy and Safety of BG2109 During Controlled Ovarian Hyperstimulation in Female Subjects Undergoing ART Procedures BG2109, Cetrorelix - Assisted Reproductive Technology, Controlled Ovarian Hyperstimulation | Phase 2 | Unknown | Bio Genuine (Shanghai) Biotech Co., Ltd. | 240 | 2023-08-01 | 2023-07-27 |
| Dydrogesterone, Cetrorelix Acetate and Triptorelin in Intra Cytoplasmic Sperm Injection Outcomes Dydrogesterone, Cetrorelix acetate, Triptorelin - IVF | Phase 3 | Unknown | Beni-Suef University | 387 | 2023-07-15 | 2023-08-02 |
| Testosterone and Neurovascular Control in Humans Cetrorelix Acetate, Testosterone gel - Healthy | Not applicable | Unknown | Western University, Canada | 20 | 2021-06-01 | 2021-03-26 |
| Coasting Versus Antagonist Protocol in Patients at High Risk of OHSS Gonadotropin, Antagonist - Ovarian Hyperstimulation Syndrome | Phase 4 | Completed | ClinAmygate | 300 | 2019-07-01 | 2019-11-21 |
| Frozen Embryo Transfer With GnRH-antagonist Trial Cetrorelix Acetate - Infertility | Phase 4 | Unknown | University of Oxford | 300 | 2018-12-13 | 2019-04-25 |
| Cetrorelix and Ganirelix Flexible Protocol for (IVF) Ganirelix Acetate, Cetrorelix Acetate - Infertility/Sterility | Phase 4 | Unknown | Università degli Studi 'G. d'Annunzio' Chieti e Pescara | 100 | 2017-11-15 | 2018-03-27 |
| Patients' Preference for Subcutaneous or Vaginal Progesterone as Luteal Support in IVF/ICSI Cycles Progesterone 25 MG subcutaneous, Micronized progesterone 200 MG, recombinant FSH - Infertility, In Vitro Fertilization | Phase 4 | Terminated | Andros Day Surgery Clinic | 60 | 2016-12-20 | 2020-01-10 |
| Delayed Start Versus Conventional Antagonist Protocol in Poor Responders Pretreated by Estradiol in Luteal Phase cetrotide - Other Complications Associated With Artificial Fertilization | Phase 3 | Completed | Cairo University | 60 | 2015-01-01 | 2016-01-27 |
| Sex Hormones and Atherosclerosis Prevention in Perimenopausal Women KUVAN, Placebo, Cetrotide - Menopause, Aging | Early Phase 1 | Completed | University of Colorado, Denver | 100 | 2013-12-01 | 2019-07-11 |
| Effect of GnRH Antagonist vs Agonist Long on IVF Outcome, Peak Estradiol Level,and Duration of Stimulation Bravelle and Menopur, Agonist, Antagonist - Fertility | Not applicable | Completed | Main Line Fertility Center | 43 | 2012-07-01 | 2014-06-04 |
| Analysis of Two Therapeutic With Cetrotide® in Polycystic Ovarian (PCO) Women in Assisted Reproductive Technology (ART) Cetrorelix acetate, Recombinant Human Choriogonadotropin (r-hCG), Recombinant human follicle stimulating hormone (r-hFSH) - Polycystic Ovarian Syndrome | Phase 3 | Completed | Merck KGaA, Darmstadt, Germany | 136 | 2008-11-01 | 2014-02-13 |
| Gonadotropin-releasing Hormone Antagonist on Triggering Day: A Randomized Controlled Study cetrorelix acetate - Infertility | Not applicable | Completed | Seoul National University Bundang Hospital | 80 | 2007-11-01 | 2009-08-21 |
| A Study to Compare the Safety and Efficacy of Cetrotide® 3 Milligram (mg) Versus Antagon™ in Women Undergoing Ovarian Stimulation Cetrotide®, Antagon ™, Recombinant human follicle stimulating hormone (r-hFSH) - Infertile Women Undergoing Assisted Reproductive Technology (ART) | Phase 4 | Completed | EMD Serono | 185 | 2003-09-01 | 2014-03-26 |
Infertility (6) · Obesity (1) · Ovarian Hyperstimulation Syndrome (1) · Polycystic Ovary Syndrome (1)
Andros Day Surgery Clinic (1) · Beni-Suef University (1) · Bio Genuine (Shanghai) Biotech Co., Ltd. (1) · Cairo University (1) · ClinAmygate (1) · EMD Serono (1) · Main Line Fertility Center (1) · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (1) · Merck KGaA, Darmstadt, Germany (1) · Seoul National University Bundang Hospital (1) · University of Colorado, Denver (1) · University of Oxford (1) · Università degli Studi 'G. d'Annunzio' Chieti e Pescara (1) · Western University, Canada (1)
Egypt (3) · Italy (2) · United States (2) · Canada (1) · China (1) · France (1) · Japan (1) · South Korea (1) · United Kingdom (1)
Adolfo Allegra, MD (1) · Ahmed M Maged, MD (1) · Chang Suk Suh, M.D., Ph.D. (1) · Eduardo Kelly, MD, MBA (1) · Eman Elgendy, MD (1) · Gian Mario Tiboni, professor (1) · Joel K Shoemaker, Ph.D. (1) · Kerrie Moreau, PhD (1) · Michael J Glassner, M.D. (1) · Sharon H. Anderson, Ph.D (1) · Xiaoyan Liang (1)
2018 (1), R56HL114073 (1)